Antibody Targeting of Stem Cells to Infarcted Myocardium

¹ Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California; University of California Berkeley and San Francisco Joint Bioengineering Graduate Group, Berkeley/San Francisco, California
² Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California
³ Immunotherapy Program, Cancer Center, Roger Williams Hospital, Department of Medicine, Boston University, Providence, Rhode Island
⁴ University of California Berkeley and San Francisco Joint Bioengineering Graduate Group, Berkeley/San Francisco, California
⁵ Department of Pediatrics, Woman and Infant's Hospital and Brown Medical School, Providence, Rhode Island
⁶ Panorama Research Inc, Mountain View, California

^* To whom correspondence should be addressed. E-mail: lee{at}medicine.ucsf.edu.

	Abstract

Hematopoietic stem cell therapy for myocardial repair is limited by the number of stem cells that migrate to, engraft in and proliferate at sites of injured myocardium. To alleviate this limitation, we studied whether a strategy using a bispecific antibody could target human stem cells specifically to injured myocardium and preserve myocardial function. Using a xenogeneic rat model whereby ischemic injury was induced by transient ligation of the left anterior descending artery (LAD), we determined the ability of a bispecific antibody to target human CD34+ cells to specific antigens expressed in ischemic injured myocardium. A bispecific antibody comprised of an anti-CD45 antibody recognizing the common leukocyte antigen found on hematopoietic stem cells (HSC) and an antibody recognizing myosin light chain, an organ-specific injury antigen expressed by infarcted myocardium was prepared by chemical conjugation. CD34+ cells armed and unarmed with this BiAb were injected intravenously in rats 2 days post-myocardial injury. Immunohistochemistry studies showed that the armed CD34+ cells specifically localized to the infarcted region of the heart, co-localized with troponin T stained cells and co-localized with vascular structures. Compared to unarmed CD34+ cells, the bispecific antibody improved delivery of the stem cells to injured myocardium and such targeted delivery was correlated with improved myocardial function five weeks following infarction (p<0.01). Bispecific antibody targeting offers a unique means to improve the delivery of stem cells to facilitate organ repair and a tool to study stem cell biology.